Implantable Defibrillators Market Report 2025

The implantable defibrillators market size has grown steadily in recent years. It will grow from $5.54 billion in 2024 to $5.73 billion in 2025 at a compound annual growth rate (CAGR) of 3.4%. The growth in the historic period can be attributed to the increased prevalence of cardiac disorders, clinical evidence and research, rise in the aging population, increased awareness and education, collaborations and partnerships.

The implantable defibrillators market size is expected to see strong growth in the next few years. It will grow to $7.21 billion in 2029 at a compound annual growth rate (CAGR) of 5.9%. The growth in the forecast period can be attributed to remote monitoring and telemedicine integration, expansion of indications, focus on heart failure management, personalized medicine approaches, and global expansion of healthcare infrastructure. Major trends in the forecast period include miniaturization and design innovations, remote monitoring and connectivity, personalized therapy approaches, leadless implantable defibrillators, and battery technology advancements.

The expected rise in the prevalence of sudden cardiac arrest is poised to drive the growth of the implantable defibrillators market. Sudden cardiac arrest (SCA) is a condition where the heart unexpectedly stops beating, and implantable defibrillators play a vital role in providing lifesaving therapy by detecting and correcting abnormal heart rhythms that may lead to SCA. According to a report by the Journal of the American College of Cardiology, SCD causes 185,000 to 450,000 deaths annually in the US population, accounting for 7% to 18% of all fatalities. Therefore, the increasing prevalence of sudden cardiac arrest is a significant factor propelling the growth of the implantable defibrillators market.

The rising incidence of diabetes is anticipated to drive the expansion of the implantable defibrillators market in the future. Diabetes is a chronic metabolic condition characterized by high blood glucose or sugar levels, which can lead to significant damage to the heart, blood vessels, eyes, kidneys, and nerves over time. Implantable cardioverter defibrillators (ICDs) are vital for managing patients with diabetes, especially those who are at risk of sudden cardiac death. Research has demonstrated that ICDs can effectively lower the rates of arrhythmic death and overall mortality in patients with severe myocardial dysfunction, including those with diabetes. For example, in June 2024, NHS England, a governing body in the UK, reported that in 2023, 3,615,330 individuals registered with a GP were diagnosed with non-diabetic hyperglycemia, also known as pre-diabetes, which represents an increase from 3,065,825 in 2022 - an approximate rise of 18%. Consequently, the growing prevalence of diabetes is fueling the growth of the implantable defibrillators market.

A noteworthy trend in the implantable defibrillators market is the emphasis on product innovations by major companies. These companies are focusing on developing new products to maintain their competitive edge. For example, in December 2023, Medtronic, an Ireland-based medical device company, introduced a novel type of implantable cardioverter-defibrillator called the Aurora extravascular ICD. Unsuch as traditional transvenous ICDs, this device is inserted under the skin beneath the left armpit, providing defibrillation during cardiac arrest and ongoing pacemaker therapies. It features Epsila leads that are minimally invasively connected to the heart beneath the breastbone. Additionally, the implant incorporates Medtronic's Smart Sense technology, aimed at reducing the risk of unwarranted shocks, and SureScan technology, allowing patients to undergo MRI tests with the device in place.

Major companies operating in the implantable defibrillators market are also focused on introducing advanced Cardiac Rhythm Management (CRM) devices with cutting-edge features to drive market revenues. These devices, equipped with innovative technology, monitor and manage cardiac issues effectively. For instance, in October 2023, MicroPort CRM, a France-based developer and manufacturer of cardiac pacemakers and implantable cardiac defibrillators, launched the ULYS Implantable Cardioverter Defibrillator (ICDs) and the INVICTA defibrillation lead in Japan. The ULYS ICD, with its cutting-edge technology and low current consumption, is expected to have a significantly longer lifespan than conventional ICD devices. The INVICTA defibrillation lead, designed to continuously detect electrical signals from the heart's right ventricle, provides defibrillation shocks or pacing therapy in the case of a potentially fatal ventricular tachyarrhythmia.

In December 2022, Johnson & Johnson Services Inc., a US-based healthcare product manufacturer, completed the acquisition of Abiomed for $16.6 billion. This strategic move allowed Johnson & Johnson to enhance its global market-leading Biosense Webster electrophysiology business by adding heart recovery technologies from Abiomed, expanding its portfolio in rapidly growing cardiovascular areas, including implantable defibrillators. Abiomed is a US-based provider of cardiovascular medical technology specializing in treating heart failure and coronary artery disease.

Major companies operating in the implantable defibrillators market include Boston Scientific Corporation, LivaNova PLC, Biotronik SE & Co KG, MicroPort Scientific Corporation, Medtronic plc, St. Jude Medical Inc., Abbott Laboratories, Sorin Group Italia S.r.l., Nihon Kohden Corporation, Koninklijke Philips N.V., Fukuda Denshi Co Ltd., Progetti S.r.l., Imricor Medical Systems Inc., ZOLL Medical Corporation, Physio-Control International Inc., Cardiac Science Corporation, Defibtech LLC, HeartSine Technologies LLC, Schiller AG, CU Medical Systems Inc., Mindray Medical International Limited, Shenzhen Mindray Bio-Medical Electronics Co Ltd., Beijing M&B Electronic Instruments Co Ltd., Bexen Cardio SL, Pacemaker Technologies, EBR Systems Inc.

North America was the largest region in the implantable defibrillators market in 2024. Asia-Pacific is expected to be the fastest-growing region in the global implanted defibrillator market forecast period. The regions covered in the implantable defibrillators market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the implantable defibrillators market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

An implantable defibrillator is a small, battery-operated device inserted into the chest to regulate abnormal heart rhythms. It continuously monitors the heart's rhythm, and if it detects a dangerous or irregular pattern, it delivers an electrical shock to restore a normal rhythm.

The primary types of implantable defibrillators include single-chambered implantable defibrillators, dual-chambered implantable defibrillators, and biventricular implantable defibrillators. Single-chamber implantable defibrillators have only one right ventricular ICD shocking coil lead placed inside the heart's right ventricle. These devices continuously monitor the patient's heart rate and rhythm and can deliver electrical shocks to the heart. The main procedures for implantation are trans-venous implantable defibrillators and subcutaneous implantable defibrillators, utilized by hospitals and clinics, ambulatory surgery centers, and other end-users.

The implantable defibrillators market research report is one of a series of new reports that provides implantable defibrillators market statistics, including implantable defibrillators industry global market size, regional shares, competitors with an implantable defibrillators market share, detailed implantable defibrillators market segments, market trends and opportunities, and any further data you may need to thrive in the implantable defibrillators industry. The implantable defibrillators market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The implantable defibrillator market consists of sales of epicardial implantable cardioverter-defibrillator, substernal implantable cardioverter-defibrillator, and single-chamber ICD with atrial sensing. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.